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Stroke is the second leading cause of death globally and represents a major cause of 
devastating long-term disability. Despite sustained efforts to develop clinically effective 
neuroprotective therapies, presently there is no clinically available neuroprotective agent for 
stroke. As a central mediator of neurodamaging events in stroke, mitochondria are recognised 
as a critical neuroprotective target, and as such, provide a focus for developing 
mitochondrial-targeted therapeutics. In recent years, cationic arginine-rich peptides (CARPs) 
have been identified as a novel class of neuroprotective agent with several demonstrated 
mechanisms of action, including their ability to target mitochondria and exert positive effects 
on the organelle. This review provides an overview on neuronal mitochondrial dysfunction in 
ischaemic stroke pathophysiology and highlights the potential beneficial effects of CARPs on 
mitochondria in the ischaemic brain following stroke. 
 
 
Keywords 
Stroke . Ischaemia . Cationic arginine-rich peptides . Mitochondria . Mito-protection . 
Oxidative stress . Membrane potential . Permeability transition . Apoptosis 
 
 
 
 
 
 
 
 
 
 
1. Stroke Background: Epidemiological ‘Snapshot’ and Need for Neuroprotection 
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Acute stroke is a global epidemic responsible for the second and third leading causes of death 
and disability respectively [1, 2]. In 2010, the global prevalence of stroke was estimated to be 
approximately 33 million, with 16.9 million individuals experiencing their first stroke [3]. A 
significant proportion of stroke survivors are left with cognitive and physical disabilities [4, 
5], or impaired language and verbal communication [6]. The burden of stroke to the global 
community is continuing to increase due to the aging world population and the increasing 
prevalence of risk factors for stroke, such as hypertension [7], diabetes [8], hyperlipidaemia 
[9], heart disease [10], obesity [11] and reduced physical activity [12–14]. As an increasing 
risk factor, the aging world population is a major concern [15], with approximately 900 
million people aged over 60, rising to an expected 1.5 billion by the year 2050 [16]. To make 
matters worse, there are currently no clinically available neuroprotective agents for the acute 
treatment of stroke to minimise brain injury, and current therapies are mainly restricted to 
endovascular recanalisation interventions for a selected subgroup of ischaemic stroke 
patients. However, most patients are ineligible for such interventions due to narrow 
therapeutic time windows (e.g. 4.5h for tPA thrombolysis) and/or the need for specialised 
tertiary hospital facilities to perform the procedure (e.g. mechanical thrombectomy). 
Notwithstanding, the recent DAWN and DEFUSE 3 clinical trials demonstrated that 
thrombectomy, when performed up to 16 to 24 hours post-stroke symptoms, could improve 
outcomes in a subgroup of patients selected on the basis of the presence of potentially 
salvageable penumbral tissue [17, 18]. For this reason it is now recommended that a “tissue 
window” rather than a “time window” be used when considering therapeutic interventions, 
such as thrombectomy and neuroprotection. Furthermore, it highlights the need for a safe 
neuroprotective agent that can be administered early after stroke onset to slow brain 
infarction and preserve penumbral tissue. 
 
Consequently, there is an urgent requirement for the development of new and more widely 
applicable neuroprotective therapies that lessen the neurological impact of stroke and 
increase the number of patients eligible for endovascular treatments. To this end, due to the 
lack of success in the past, there is growing sentiment that new approaches in the discovery 
and development of acute neuroprotection therapies will be required.  
 
The main purpose of this review is to examine the role of mitochondrial dysfunction in stroke 
pathophysiology, and in doing so highlight the beneficial effects that neuroprotective cationic 
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arginine rich peptides (CARPs) may exert on mitochondria in neurons in the ischaemic brain 
following stroke. 
 
2. Mitochondrial Dysfunction in Stroke Pathophysiology 
2.1 Underlying stroke injury mechanisms: The ischaemic cascade 
Ischaemic stroke results from the acute occlusion of a cerebral artery by thrombosis or 
embolism, and constitutes the bulk of stroke events, accounting for approximately 80% of 
cases [19], and as such, will be the main focus of this review. Ischaemic stroke 
pathophysiology is initiated by a sudden reduction in blood flow to the affected brain tissue, 
causing a deficiency in oxygen and glucose supply, triggering what is known as the 
ischaemic cascade (Figure 1) [20, 21]. The ischaemic cascade is influenced by the duration 
and severity of ischaemia [22], which usually culminates in the time-dependent death of 
neuronal tissue. Acute injury occurs within minutes in severely affected brain tissue in the 
ischaemic core, which represents an area of infarcted or irreversibly damaged brain tissue, 
and cannot be salvaged. Surrounding the ischaemic core is the potentially salvageable tissue 
known as the penumbra, which is affected by ischaemia, although to a lesser extent than in 
the core, and consequently has not succumbed to cell death. Brain injury in the penumbra can 
proceed over many hours, and is the target of endovascular recanalisation interventions (tPA 
and thrombectomy) and neuroprotective treatments. However, in the absence of adequate 
reperfusion or a neuroprotective therapy, the on-going and cumulative cellular injury, 
including the demise of mitochondria, reaches a critical threshold, and neurons become 
irreversibly committed to dying and are incorporated into the ischaemic core. 
 
Mitochondria are key regulators in determining the fate of ischaemic brain tissue, as they are 
both affected by and are propagators of ischaemic injury. Furthermore, neuronal 
mitochondrial disturbances have also been identified as key contributors to the 
pathophysiology of several chronic neurological disorders, including Parkinson’s disease  
[23], Alzheimer’s disease [24], and Huntington’s disease [25–33]. Another consideration is 
that mitochondrial bioenergetics naturally decline with age, largely as a result of accumulated 
oxidative damage to mitochondrial DNA, proteins, and lipids [34–37]. As a consequence, 
aged mitochondria are more likely to be vulnerable to the effects of cellular energy 
disturbances, as occurs in ischaemic stroke [38]. This has additional implications in stroke, as 
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most strokes occur in individuals over the age of 65 [39], and age-related decline in 
mitochondrial function may result in an increased susceptibility to ischaemic brain injury. In 
this context, mitochondria represent critical targets for the development of neuroprotective 
strategies for stroke and other neurological disorders, and as such, their role in the ischaemic 
cascade is described in detail below.  
 
2.2 Biomolecular mechanisms underlying mitochondrial dysfunction during stroke 
 
Energy failure and excitotoxicity: Glutamate and calcium  
During ischaemic stroke, neuronal mitochondrial function is severely compromised due to the 
reduced availability of glucose and oxygen necessary for ATP production, a situation which 
is exacerbated by the high energy demand of neuronal tissue [40, 41]. The resulting 
disruption to the mitochondrial electron transport chain (ETC) halts oxidative 
phosphorylation, forcing cells to rely on anaerobic glycolysis for ATP production [42]. 
However, due to the limited supply of glucose, glycolysis is also severely compromised. 
Since ATP is required for the maintenance of ion gradients across neuronal plasma 
membranes [43], the resulting energy failure triggers the depolarisation of neurons and 
uncontrolled release of excitatory neurotransmitters, in particular glutamate, from pre-
synaptic neurons [42]. High extracellular levels of glutamate cause excitotoxicity due to the 
overstimulation of post-synaptic glutamate receptors [44, 45], including N-methyl-D-
aspartate (NMDA) and -amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) 
receptors, thereby causing prolonged depolarisation and toxic accumulation of calcium and 
sodium within neurons [46–48] (Figure 1). High levels of intracellular calcium are 
particularly toxic to neurons due to its involvement in the activation of proteolytic enzymes 
and lipases, free radical formation and oxidative stress, mitochondrial dysfunction, cell death 
signalling, and cytotoxic oedema [47, 49–52]. It is therefore not surprising that the inhibition 
of excitotoxic intracellular calcium influx is invariably neuroprotective [53–56].  
 
Mitochondria and intracellular calcium  
As a consequence of excitotoxic intracellular calcium disturbances, mitochondria can act as a 
buffer to help regulate cytosolic calcium concentrations and minimise toxic effects [57–60]. 
Mitochondria sequester calcium through several mechanisms including the mitochondrial 
calcium uniporter (MCU) [59–61], mitochondrial sodium-calcium exchanger (mNCX) [62], 
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voltage-dependent anion channel (VDAC) [63], “rapid-mode” of uptake (RaM) [64], and the 
mitochondrial-located ryanodine 1 receptor (mRyR) [65, 66] (Figure 1). However, during 
severe excitotoxicity and ongoing ionic disturbances, the buffering capabilities of 
mitochondria can become overwhelmed, leading to excessive intra-mitochondrial calcium 
concentrations and disruption of mitochondrial function [67, 68]. Although mitochondria are 
capable of extruding excess calcium via the mNCX, this exacerbates the toxic cytosolic 
calcium loading [69, 70]. Mitochondria also co-operate with the endoplasmic reticulum (ER) 
to help maintain cellular calcium homeostasis via the mitochondria-associated ER membrane 
(MAM), allowing the organelles to collaborate in calcium ion exchange [71]. In spite of this, 
the ER can be an additional source of cytosolic calcium following release of excess calcium 
via the ryanodine (RyR) and inositol triphosphate (IP3R) receptors [72]. Furthermore, 
cytochrome c (cyt c), a protein involved in the mitochondrial ETC and apoptosis, is released 
from dysfunctional mitochondria and can translocate to the ER to selectively bind IP3Rs 
(Figure 1), causing prolonged release of calcium from the organelle, and thereby sustaining a 
toxic feedback loop know as calcium-induced calcium release (CICR) [73]. Ultimately, the 
excessive and sustained intra-mitochondrial accumulation of calcium significantly impacts 
mitochondrial function, and is a potent trigger for mitochondrial reactive free radical species 
generation, which further impacts the function of the organelle and cell viability (Figure 2).   
 
Oxidative and nitrosative stress and mitochondria   
Stroke is associated with oxidative stress resulting from the overproduction of reactive 
oxidative species (ROS) and reactive nitrosative species (RNS), which overwhelms 
endogenous neuronal antioxidant defence mechanisms, leading to damage to cellular 
components [74]. During stroke, mitochondria generate an initial burst of ROS, including 
superoxide anion (O2
•-), hydroxyl radical (•OH), and hydrogen peroxide (H2O2) [75–78]. 
Such oxidants cause considerable damage to brain tissue due to the brain’s large 
polyunsaturated fatty acid composition and limited antioxidant defensive capabilities [79]. 
Mitochondrial ROS generation is primarily derived from the ETC, with complexes I and III 
generating the bulk of ROS through ‘electron leak’ [80]. Auto-oxidation of ‘leaked’ electrons 
to oxygen forms the free oxygen radical O2
•- [75, 81], which is converted into H2O2 by 
endogenous manganese superoxide dismutase (MnSOD) [82]. Mitochondrial catalase and 
peroxiredoxin can convert H2O2 into H2O [83]. However, the abundance of iron sulfur 
clusters and iron containing heme groups associated with ETC proteins, such as those present 
in complexes I, II and III [84], provide a bountiful source of iron for generation of •OH from 
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H2O2 via the Fenton reaction [85] (Figure 2). Mitochondria are also major contributors to the 
ROS generation that occurs during spontaneous reperfusion or following therapeutic 
endovascular recanalization after stroke. Although timely restoration of cerebral blood flow is 
of primary importance in preventing further injury during stroke, the sudden reoxygenation of 
brain tissue can trigger what is known as ‘reperfusion injury’. Reperfusion reintroduces 
molecular oxygen to oxygen-starved tissue and provides a fresh source of substrates causing 
a surge in ROS formation [75], which places additional stress on mitochondria already 
affected by ischaemia. 
 
Mitochondria are also the target of RNS due to the excessive production of nitric oxide (NO•) 
during stroke [86, 87]. NO• plays an important role in excitotoxicity-mediated injury and is 
generated through neuronal nitric oxide synthase (nNOS) linked to neuronal NMDA receptor 
signalling [88]. During overactivation of NMDA receptors, calcium influx activates nNOS, 
producing NO•, which then interacts with mitochondrial-generated O2
•- to produce the highly 
volatile peroxynitrite species (ONOO-) [89–91]. Both NO• and ONOO- react with 
mitochondrial membranes and other lipid membranes, as well as eliciting S-nitrosylation and 
activation of pro-death proteins, including caspases and matrix metalloproteinases [89, 92, 
93] (Figure 2). Furthermore, ROS/RNS-induced damage of ETC components, particularly the 
ETC anchoring phospholipid, cardiolipin, exacerbates ROS generation arising from enhanced 
electron ‘leak’, resulting in mitochondria not only acting as propagators of ROS formation, 
but also targets of ROS-induced injury [94, 95].  
 
Free radical oxidation of cardiolipin is particularly detrimental as the phospholipid plays an 
important role in maintaining inner mitochondrial membrane (IMM) structure and anchoring 
ETC complexes to the IMM to ensure optimal mitochondrial bioenergetics [96, 97]. 
Furthermore, due to cardiolipin’s high unsaturated fatty acid content and its close proximity 
to the site of mitochondrial ROS production, it is highly susceptible to oxidative damage [95]. 
As a consequence, oxidised cardiolipin can lead to further destabilisation of the ETC, as well 
as promoting the detachment of cyt c from the IMM and its release from mitochondria [98].  
Furthermore, the interaction of oxidised cardiolipin with cyt c bestows peroxidase activity to 
the protein capable of catalyzing H2O2-dependent peroxidation, causing further oxidation of 
cardiolipin [99]. 
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Together, excessive mitochondrial ROS/RNS generation perpetuates cellular injury by 
attacking mitochondrial and cytoplasmic lipid membranes, proteins and DNA, causing 
cellular damage that contributes to neuronal cell death [100–102]. 
 
The mitochondrial membranes and mitochondrial membrane potential 
The outer mitochondrial membrane (OMM) is a selectively permeable phospholipid bilayer 
that controls the transport of substances in and out of the organelle via membrane-bound 
transporter complexes. For example, the OMM voltage-dependent anion channel (VDAC) 
facilitates the exchange of various ions and small uncharged molecules [103]. Similarly, 
selective cytosolic protein and peptide import across the OMM is achieved via multi-subunit 
conductor complexes known as ‘translocase of outer mitochondrial membrane’ (TOM) 
channels [104]. The inner mitochondrial membrane (IMM) is also a phospholipid bilayer that 
is extensively folded and is embedded with proteins comprising the ETC, as well as other 
conductance protein channels known as ‘translocase of the inner membrane’ (TIMs), which 
form a supercomplex with TOMs that communicate across the intermembrane space, and are 
responsible for the exchange of pre-proteins from the intermembrane space into the 
mitochondrial matrix [105, 106]. Crucially, the ETC is responsible for generating the 
electrochemical gradient across the IMM, known as the mitochondrial membrane potential 
(Δψm), which is necessary for energy production via oxidative phosphorylation [107] (Figure 
2). The Δψm is an integral part of the proton motive force (p) generated by the ETC and 
used by ATP synthase to generate ATP [108, 109]. The Δψm is also critical for mitochondrial 
function and cell viability, as it is a primary factor that determines mitochondrial respiration, 
calcium sequestration capacity, and ROS production, all of which play a critical role in 
determining the fate of neurons during ischaemia [110]. 
 
During stroke, the excessive accumulation of calcium in the mitochondrial matrix can trigger 
hyperpolarization, and subsequently depolarization of the IMM and dissipation of the Δψm 
[78], leading to impaired ATP production [111, 112]. In an attempt to maintain the multitude 
of Δψm-dependent processes critical for mitochondrial function, mitochondrial ATP synthase 
acts in reverse (F1Fo-ATPase) and hydrolyzes ATP to conserve the Δψm. However, due to 
the ongoing effects of ischaemia, the depletion of mitochondrial and cytosolic ATP further 
exacerbates loss of mitochondrial integrity and activation of cell death cascades [113, 114]. It 
is considered that the complete dissipation of the Δψm in a large proportion of mitochondria 
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within a cell is one of the earliest indicators of irreversible cell death [115]. It is for these 
reasons that interventions that restore and/or preserve the Δψm can improve the likelihood of 
cell survival, and therefore represent potent therapeutic interventions for neuroprotection 
[116–118].  
 
Mitochondrial outer membrane permeabilization and cell death signalling  
Neuronal mitochondrial dysfunction culminates in mitochondrial membrane 
permeabilization, which is a critical event in promoting pro-death signalling pathways via the 
release of cell death-promoting molecules from the intermembrane space into the cytosol. 
Mitochondrial-mediated cell death can proceed by two different mechanisms depending on 
either apoptotic or necrotic stimuli (see comprehensive reviews by [119, 120]). Classic 
mitochondrial-mediated apoptotic cell death is instigated by the recruitment of pro-death Bcl-
2 family member proteins, Bad and Bax, to the OMM [121]. Oligomerization of Bad and Bax 
in the OMM triggers mitochondrial outer membrane permeabilization (MOMP), which 
releases pro-apoptotic factors such as cyt c [122], apoptosis inducing factor protein (AIF) 
[123, 124], second mitochondria-derived activator of caspase/direct inhibitor of apoptosis 
protein (IAP)-binding protein with low pI (Smac/DIABLO), and endonuclease G (Endo G) 
[125] from the intermembrane space into the cytosol [126]. The release of the pro-cell death 
factors together orchestrates an interconnected process resulting in the dismantling of cell 
structures, contributing to the demise of the cell [127] (Figure 1). 
 
Additionally, mitochondria play a role in necrotic cell death associated with elevated ROS 
generation and mitochondrial calcium loading. The toxic effects of ROS and calcium influx 
on mitochondria causes permeabilization of the IMM, known as permeability transition (PT), 
and results in the formation of the highly conductive mitochondrial permeability transition 
pore (mPTP) spanning the inner and outer mitochondrial membranes. The mPTP facilitates 
influx of calcium and other solutes into the mitochondrial matrix [128, 129]. Sustained mPTP 
conduction also contributes to mitochondrial ROS release [130], which in turn maintains 
mPTP opening in a self-propagating cycle known as ROS-induced ROS release (RIRR) (see 
review [78]). Influx of calcium into the matrix causes equilibration of the proton gradient and 
collapse of the Δψm, further enhancing ROS generation and metabolic inhibition [131, 132]. 
Furthermore, the increasing osmotic pressure from mitochondrial calcium accumulation 
causes the matrix to swell beyond the limits of the OMM, eventually rupturing the OMM and 
liberating calcium in addition to the aforementioned mitochondrial pro-death factors into the 
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cytosol. This stimulates proteases, nucleases, and lipases, causing subsequent degradation of 
cellular proteins, DNA, and membrane lipids, leading to necrotic cell death [133, 134].  
 
Mitochondrial fusion and fission 
As an adaptive response to metabolic and oxidative stress, mitochondria can rapidly alter 
their structural architecture through a process of fusion and fission. Mitochondrial fusion 
involves the joining of mitochondria in order to allow compensatory functions between 
healthy and metabolically challenged mitochondria [135], and thereby helps to preserve 
overall mitochondrial integrity [136, 137]. Fused mitochondria have a filamentous 
morphology comprising a large interconnected metabolic network that can span over a 
hundred microns across a single cell to enable the supply of ATP to energy-deficient cellular 
regions [138–140]. The ability of mitochondria to fuse is particularly important in the context 
of post-mitotic cells, such as neurons, as it provides a means of minimising the toxic effects 
of dysfunctional mitochondria without triggering cell death [35]. The process of 
mitochondrial fusion is controlled through the actions of the dynamin GTPase family 
members, mitofusins (Mfn1, Mfn2) and optic atrophy 1 (Opa1), which act on the OMM and 
IMM, respectively [141].  
 
Similarly, mitochondrial fission represents a mechanism whereby the organelle can divide in 
an attempt to segregate mitochondrial damage, and eliminate dysfunctional mitochondria by 
mitophagy. Mitochondrial fission is mediated by the dynamin GTPase family member, Drp1 
[142], as well as Fis1 [143], which act on the OMM and IMM respectively. However, 
mitochondrial fragmentation resulting from excessive mitochondrial fission, as well as the 
altered ability of cells to undergo mitochondrial fission, have been linked to neuronal injury 
and neurodegeneration [144–146]. 
 
With respect to stroke-mediated injury, NMDA receptor overactivation of cultured neurons is 
associated with excessive mitochondrial fragmentation, and promotion of mitochondrial 
fusion reduces excitotoxic cell death [147]. Similarly, Drp1 inhibition, which blocks 
mitochondrial fragmentation, reduces cell death in cortical neuronal cultures subjected to 
glutamate excitotoxicity [148]. In addition, it has been demonstrated in HeLa cells that the 
release of cyt c from mitochondria is accelerated as a consequence of down-regulation of 
OPA1, a dynamin-like GTPase required for mitochondrial fusion, and precedes mitochondrial 
fragmentation [149], indicating a temporal link between induction of mitochondrial pro-death 
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signalling and mitochondrial fragmentation. This is corroborated by several reports 
demonstrating mitochondrial fragmentation coinciding with ischaemic neuronal injury [150–
153]. Taken together, it appears that strategies that promote mitochondrial fusion or inhibit 
excessive fission represent potential neuroprotective interventions to minimize neuronal 
death following stroke and possibly other acute and chronic neurodegenerative disorders.  
 
3. CARPs as Mitochondria-Targeted Neuroprotective Therapeutics   
 
3.1 Neuroprotection in stroke and CARPs: A brief history 
 
In the context of stroke, a ‘neuroprotective agent’ refers to any compound that has the 
capacity to slow and/or halt the progression of infarct development by inhibiting 
neurodamaging processes and/or by stimulating cell survival pathways [154]. To date, while 
over 1000 novel potential neuroprotective therapeutics have been identified, many of which 
demonstrated efficacy in preclinical animal studies [155], none have returned positive 
outcomes in clinical trials. While there are many reasons for previous failures to translate into 
clinical efficacy (e.g. late administration of the agent after stroke, undesirable side-effects, 
ineffective drug targets, single pathway/mechanism of action, and study design), as 
mitochondria are a central component in many of the critical aspects of the ischaemic 
cascade, they represent a key target in the development of neuroprotective strategies. To this 
end, a class of inherently neuroprotective peptides, known as CARPs have emerged as 
candidates for mitochondria-targeted therapeutics in stroke and other acute and chronic CNS 
disorders, as well as ischaemic injury in other tissues, including myocardial and renal tissue 
[156–162]. 
 
3.2 Features and membrane-traversing properties of CARPs 
 
CARPs typically range in size from 4 to 30 amino acids, and are positively charged due to the 
presence of cationic arginine residues, as well as cationic lysine and to a lesser extent 
histidine residues [163, 164] (Table 1). An important feature of CARPs is their ability to 
traverse cell membranes and enter cells and mitochondria, and for this reason they are also 
known as cell-penetrating peptides (CPPs) [165]. The ability of CARPs to traverse cell 
membranes is a direct result of peptide arginine content, namely the positive charge provided 
by the guanidinium head that is unique to the arginine amino acid [166–169]. To this end, the 
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guanidinium head group can form bidentate hydrogen electrostatic interactions with sulphate 
(e.g. in heparin sulphate proteoglycans), phosphate (e.g. in phospholipid head groups) and 
carboxylate (in phospholipid phosphatidylserine and protein receptors) moieties present on 
the plasma membrane or organelle membrane structures, such as those present in 
mitochondria, Golgi apparatus, endoplasmic reticulum, or the nucleus [170–174]. The 
electrostatic interactions between arginine residues and anionic structures present on 
membranes is a critical requirement for CARPs to cross typically impervious membranes, 
including the blood-brain barrier [163, 164, 175, 176], via both endocytic (e.g. 
macropinocytosis, caveolin/lipid-raft-mediated and clathrin-mediated endocytosis) [177, 178] 
and non-endocytic (e.g. passive diffusion, inverted micelle) mechanisms [173, 179–182].  
CARP membrane-traversing efficacy is dependent on peptide arginine content, by increasing 
peptide positive charge and guanidinium head group electrostatic interactions with membrane 
anionic moieties. This was demonstrated by significantly reduced translocation capabilities of 
the TAT CPP when arginine residues were replaced with the alternative cationic amino acids, 
ornithine, histidine, and lysine, which are less basic compared to arginine and lack a 
guanidinium head group [183]. Furthermore, peptide cellular uptake was enhanced when the 
arginine content was increased [184]. With respect to arginine content and peptide length, 
CARP transduction efficiency across the plasma membrane, at least for poly-arginine 
peptides, is detectable with R6 (6 mer arginine) and peaks with R15 [183]. In addition, CARP 
membrane-traversing capabilities can be enhanced by presence of other residues, particularly 
the hydrophobic amino acid, tryptophan [185], and a high transmembrane potential [186]. 
The cell penetrating properties of CARPs are particularly useful in the context of 
neuroprotection, as one of the main obstacles in drug delivery to the CNS is transport across 
the blood-brain barrier and entry into the brain. 
Interestingly, and of particular importance in the context of mitochondria-targeted peptides, is 
that the presence of a transmembrane potential is a crucial element for ability of guanidinium-
rich CARPs to traverse membranes [186]. Regarding mitochondria, the Δψm [163, 166, 187] 
and the presence of the negatively charged mitochondrial membrane phospholipid, 
cardiolipin [188], provides the ideal electrostatic attractive forces that enable CARPs to target 
this organelle. The guanidinium head groups of CARPs is also the likely source of their 
antioxidant capabilities, due to their innate free radical scavenging properties [189–192], 
making them perfectly suited to combat mitochondrial-generated ROS and/or cytosolic ROS 
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originating from membrane-bound NADPH oxidase during ischaemia [193], which is 
encouraged by the deleterious crosstalk between the two sources [194, 195].  
By targeting mitochondria, CARPs can exert mito-protective effects on the organelle and by 
extension help maintain cell viability during times of stress, as occurs following ischaemia 
[196]. To date, a number of CARPs have been shown to target mitochondria, and have been 
examined in stroke and other brain injury models (Figure 3, Table 2), several of which are 
discussed in detail below. It should be noted that while they are outside the scope of this 
review, there are several non-peptide neuroprotective agents that potentially overlap 
mechanistically with CARPs by way of their guanidinium head groups, including metformin, 
phenformin and agmatine [197–201].  
 
3.3 Pharmacokinetics of CARPs 
 
While free CARPs are likely to have a serum half-life of several minutes, CARPs bound to 
serum proteins are likely to have a serum half-life of several hours [202–205]. For example, 
serum proteins such as albumin and α1-acid glycoprotein bind CARPs, providing a reservoir 
of the peptide that prolongs serum half-life and potentially extending peptide therapeutic 
duration [203, 206, 207]. Furthermore, various peptide structural modifications such as 
cyclization and use of D-enantiomer amino acids can enhance resistance to serum proteases, 
and thus improve serum stability [206, 208, 209]. With regards to tissue targeting, CARPs 
and CARP-conjugates generally exhibit preferential distribution in kidney, liver, spleen, lung 
and to a lesser extent brain [203, 204, 210–216]. While the ability of CARPs to target brain 
tissue is relatively modest, this may be advantageous in terms of reducing undesirable 
neurological side effects, while still providing the desired therapeutic effects [203]. 
Furthermore, the increased permeability of the blood-brain barrier during ischaemic stroke is 
likely to increase uptake into the brain and prolong the presence of CARPs within ischaemic 
tissue [217].  
 
3.4 Non-mitochondrial neuroprotective mechanisms of CARPs 
 
There is growing evidence that CARPs, in addition to possessing mito-protective properties 
are plurifunctional in terms of their neuroprotective mechanisms of action. For example, 
studies in our laboratory have demonstrated that CARPs, including the TAT-fused NA-1 
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peptide (TAT-NR2B9c), have the capacity to not only reduce glutamic acid induced 
excitotoxic neuronal death and intracellular calcium influx [160, 161, 218–220], but also 
reduce neuronal surface expression of the NMDA receptor subunit protein NR2B [221]. 
CARPs also have the capacity to reduce the activity and/or surface expression of other ion 
channels and receptors (e.g. AMPAR, NCX, TRPV1, CaV2.2, CaV3.3) that may exacerbate 
excitotoxic ionic disturbances in the brain following stroke [221–231], and is one likely 
mechanism whereby the peptides reduce the damaging effects of glutamate-induced 
excitotoxicity. In addition to the confirmed neuroprotective properties of CARPs, they 
possess other properties that may be beneficial following stroke; they induce the 
internalization of cell surface TNF receptors [231], scavenge free radicals and reduce lipid 
peroxidation [189–192], inhibit the activity of the proteasome [232–234], reduce 
inflammatory responses [235–241], activate pro-cell survival signalling [218, 229, 242], and 
inhibit pro-protein convertases that activate matrix metalloproteinases [243–245].  
 
3.5 Preclinical and clinical efficacy of CARPs as mitochondria-targeted therapeutics 
for stroke 
 
Szeto-Schiller (SS) peptides  
Szeto-Schiller (SS) peptides possess cytoprotective and mitoprotective properties and consist 
of four amino acids in length, with a net positive charge of +3 due to the presence of one 
arginine and one lysine or ornithine residue, and C-terminal amidation [246]. The SS peptides 
are synthesised with alternating cationic and aromatic residues, with five peptides being best 
characterised (SS-01: YrFK-NH2; SS-02: DmtrFK-NH2, SS-20: FrFK-NH2; SS-31: rDmtKF-
NH2; mtCPP-1: rDmtOF-NH2; r = D-arginine, Dmt = 2,6-dimethyltyrosine, O = ornithine). It 
is likely that the combination of the arginine residue and cationic charge are the reason that 
SS peptides are able to traverse plasma and mitochondrial membranes.  
 
In vitro studies examining the cytoprotective properties of SS-peptides have revealed several 
potential mechanisms of actions. With respect to mitochondrial targeting, it has been 
estimated that SS peptides can translocate within mitochondria at a 100-5000-fold higher 
concentrations compared to the extramitochondrial cytosolic compartment [247, 248]. 
Furthermore, SS peptides concentrate in the IMM, where they are believed to interact with 
and stabilize cardiolipin during oxidative stress, and thereby help preserve the IMM 
bioenergetics and reduce ROS production [249]. In addition, the ability of SS peptides to 
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target and stabilise IMM cardiolipin is considered a mechanism that inhibits disengagement 
of cyt c from cardiolipin and its release from mitochondria into the cytosol [248, 250]. While 
the exact mechanisms for the beneficial effects of SS peptides on IMM cardiolipin are not 
fully known, the ability of the cationic guanidinium group present on arginine residues to 
interact with anionic phosphate groups of cardiolipin (−2 net charge) may be involved. 
 
There is also evidence that SS peptides have direct antioxidant properties, which would also 
reduce mitochondrial ROS levels. For example, in vitro studies have demonstrated that SS-31 
quenches the ROS H2O2, 
•OH and ONOO-, and SS-02 quenches H2O2 [248, 251]. The ROS-
quenching effects of SS-31 have been demonstrated in a mouse model of hypertensive 
cardiomyopathy [252], and its ability to restore mitochondrial ATP production has also been 
shown in a murine model of ischaemic kidney injury [157]. Furthermore, positive results with 
SS-31 have been obtained in a mouse stroke model, as demonstrated by Cho et al. (2007) 
whereby intraperitoneal administration of SS-31 (2 and 5 mg/kg; 3000 and 7150 nmol/kg) 
immediately, as well as 6, 24, and 48 hours after a 30 minute duration of MCAO significantly 
reduced infarct volume [253].  
 
The most recently developed SS peptide, mtCPP-1, has superior mitochondrial uptake and 
superoxide scavenging abilities than SS-31 [254]. The mtCPP-1 peptide differs from SS-31 
by the substitution of the lysine (K) residue with an ornithine (O) residue. While no 
explanation has been provided for the improved mito-protective effects of mtCPP-1 over SS-
31, Rigobello et al. (1995) demonstrated in isolated rat liver mitochondria that the ornithine 
tetramer (OOOO; O4) was more effective than the lysine tetramer (KKKK) at maintaining 
mitochondrial permeability transition and membrane potential induced by calcium. 
Importantly, the arginine tetramer (RRRR; R4) was even more effective than O4 at inhibiting 
the toxic effects of calcium on mitochondrial permeability transition and membrane potential 
[255], which further highlights the critical importance of arginine content for the mito-
protective benefits of CARPs. 
 
Poly-arginine and related CARPs 
In addition to SS peptides, longer chain CARPs, including poly-arginine peptides and cell 
penetrating peptides (CPPs), exhibit neuroprotective properties [219, 256, 257]. Initial reports 
from our laboratory and other laboratories demonstrated that the cationic arginine-rich CPP, 
TAT48-57 (TAT: GRKKRRQRRR; net charge +9; arginine residues 6), displayed modest 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
neuroprotective actions in both in vitro and in vivo stroke models [256, 258–261]. These 
findings were in line with an earlier study by Ferrer-Montiel et al (1998), demonstrating that 
cationic arginine-rich hexapeptides (net charge +3 - +7; Arginine residues 2 - 6) were 
neuroprotective in a hippocampal neuronal NMDA excitotoxicity model [262]. Subsequent 
studies in our laboratory showed that poly-arginine-9 (R9; 9 mer of arginine) and penetratin 
were 17-fold and 4.6-fold respectively, more neuroprotective than TAT in a cortical neuronal 
glutamate excitotoxicity model [256]. Further studies in our laboratory revealed that other 
poly-arginine peptides and CARPs as a group are highly neuroprotective, with efficacy 
increasing with increasing peptide arginine content and positive charge, peaking at R15 to 
R18 for poly-arginine peptides [219]. In addition, we have demonstrated that different amino 
acids can increase (e.g. tryptophan) or decrease (e.g. alanine) the neuroprotective efficacy of 
CARPs following glutamate excitoxicity [257], and that CARPs can reduce excitotoxic 
neuronal calcium influx and cell surface expression of the NR2B NMDA receptor subunit 
protein [221]. Interestingly, it appears that the ability of CARPs to traverse cellular 
membranes is correlated to peptide neuroprotective efficacy [161, 219, 257]. While the exact 
reason for this correlation is not fully known, it may be related to the ability of CARPs to 
modulate plasma receptor function or expression levels [216, 218, 258], and/or the ability of 
CARPs to reach therapeutic concentrations within the cell cytosol and organelles (e.g. 
mitochondria, nucleus, endoplasmic reticulum) by virtue of their cationic charge.  
 
The neuroprotective properties of CARPs, including poly-arginine peptides, was further 
validated by Marshall et al (2015), who demonstrated the ability of CARPs to reduce 
NMDA-induced retinal ganglion cell death in the retina of rats. In addition, an R7 poly-
arginine peptide with a cysteine di-sulphide bridge (C-s-s-C-R7: C-s-s-CRRRRRRR-NH2) 
reduced mitochondrial oxidative stress in retinal ganglion cells following NMDA exposure, 
and localised to mitochondria in HEK293 cells. Furthermore, in HEK cells R7 and C-s-s-C-
R7 reduced mitochondrial respiration, m, and ROS generation, and it was proposed that 
these effects on mitochondria would be neuroprotective for neurons during metabolic stress 
(e.g. excitotoxicity and ischaemia) [264]. 
 
With respect to stroke, we have demonstrated in experimental studies in the rat that the poly-
arginine peptides R9D, R12, R18, R18D (D = D-isoform) and protamine all reduce infarct 
volume following permanent and/or transient middle cerebral artery occlusion (MCAO) and 
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perinatal hypoxia-ischaemia, and also reduce the severity of traumatic brain  injury [162, 
265–269], further confirming the efficacy of CARPs in a pre-clinical stroke setting. 
 
TAT and other cationic arginine-rich CPP-fused neuroprotective peptides  
The TAT peptide was first characterised for its cell penetrating properties by Frankel and 
Pabo (1988) [270]. Since then, many studies have used TAT and related cationic arginine-
rich CPPs (CCPPs) (e.g. R9, penetratin) fused to “putative” neuroprotective peptides for 
application in stroke and other acute CNS injury pre-clinical neuroprotection studies, with 
most returning positive results [258, 260, 261, 271–276]. However, given the unequivocal 
neuroprotective properties of CARPs, several years ago we proposed that the neuroprotective 
effects of “putative” neuroprotective peptides fused to CCPPs, which are CARPs, was 
largely, if not exclusively mediated by the carrier peptide [219, 257]. In this context, it is also 
likely that the cargo peptide can further enhance the neuroprotective efficacy of CCPPs by 
providing additional arginine residues, other positively charged amino acids (e.g. lysine) or 
amino acids that increase CARP neuroprotective efficacy (e.g. tryptophan), as well as 
providing structural stability. Importantly, studies in our laboratory [219, 221, 257] and by 
Marshall et al. (2015), and more recently McQueen et al. (2017), support a CARP-mediated 
neuroprotective mechanism for “putative” neuroprotective peptides fused to CCPPs (e.g. 
TAT-NR2B9c and TAT-NR2Bct) [264, 277] (for more detail on this subject, see Meloni et 
al. 2015b). Therefore, based on the findings from our and other laboratories, we believe that 
past neuroprotective studies that have utilized CCPPs need to be critically re-evaluated.   
 
Despite the confounding neuroprotective effects of the carrier peptide in studies using 
“putative” neuroprotective peptides fused to CCPPs, it is likely that due to their cationic and 
arginine-rich properties, these peptides have the capacity to target and exert beneficial effects 
on neuronal mitochondria following stroke. While it will be important for future studies to 
confirm the mito-protective properties of neuroprotective peptides fused to CCPPs, it is 
encouraging that so many studies have returned positive results in stroke and other acute and 
chronic neuronal injury models [226, 256, 274, 278–291]. To this end, the TAT-fused 
neuroprotective peptide TAT-NR2B9c, now known as NA-1, is currently being assessed in 
two Phase III clinical stroke trials (ESCAPE-NA-1 and FRONTIER). It is noteworthy in this 
regard that based on studies from our and other laboratories, other CARPs including poly-
arginine peptides (e.g. R18) display even greater neuroprotective efficacy than NA-1 in 
stroke and related neuronal injury models [162, 257, 264, 265, 267].  
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Borna disease virus X protein  
The X protein derived from the Borna virus (BVD-X) is a cationic protein containing 11 
arginine residues that has mitochondriotropic and mito-protective capabilities. It was 
demonstrated to localise in mitochondria in rat C6 astroglioma cells, and was shown to 
prevent apoptosis in response to both extrinsic (10 µg/mL α-Fas) and intrinsic (50 µM 
peroxynitrite) pathway stimuli in HEK293T and mouse L929 cells, respectively [292].   
 
In relation to neuroprotection, Szelechowski et al. (2014) demonstrated that in neurons over-
expressing BVD-X, the protein localised to mitochondria and reduced rotenone–induced 
axonal fragmentation. Furthermore BVD-X preserved mitochondrial bioenergetics by 
preventing rotenone-induced loss of Δψm and subsequent ROS generation. In addition, it was 
demonstrated that when administered stereotaxically into the substantia nigra pars compacta, 
BVD-X provided neuroprotection in a mouse MPTP Parkinson’s disease model [293]. A 
peptide derived from BVD-X (SRPAPEGPQEEPLHDLRPRPANRKGAAVE) and fused to a 
CCPP and mitochondrial penetrating peptide (FRchaKFRchaK; cha = cyclohexyl-alanine), 
termed PX3, (net charge +4.1, arginine residues = 6), when administered intranasally also 
reduced MPTP-induced neurodegeneration in mice. PX3 also accumulated within 
mitochondria of cultured neurons and protected axons against rotenone-induced axonal 
fragmentation, which corresponded to reduced levels of mitochondrial fission and the 
retention of a greater proportion of filamentous over fragmented mitochondria within 
neurons. Interestingly, both BVD-X and PX3 were shown to reduce Drp1 phosphorylation in 
neurons exposed to rotenone, which is a signalling event known to stimulate mitochondrial 
fission [293]. In a subsequent study, the same group demonstrated that introduced mutations 
of the BVD-X protein designed to enhance mitochondrial localization resulted in greater 
efficacy against rotenone-induced mitochondrial stress in cortical neuronal cultures, an effect 
that correlated with enhanced mitochondrial filamentation and reduced fragmentation [294]. 
 
It is important to note that while the efficacy of the BVD-X derived peptide PX3 has yet to be 
explored in stroke injury models, its neuroprotective actions in terms of maintaining 
mitochondrial structural integrity provides further insight into the potential mechanisms 
whereby CARPs may be neuroprotective in stroke. 
 
4. Conclusions and Future Perspectives 
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With ischaemic stroke constituting one of the leading causes of global morbidity and 
mortality, the development of effective neuroprotective therapeutics is of paramount 
importance and an urgent priority. Mitochondria are an exciting focus for developing novel 
neuroprotective agents, particularly in view of the critical role they play in homeostatic 
cellular processes, including the generation of cellular ATP and regulation of intracellular 
calcium homeostasis. Furthermore, as a consequence of cerebral ischaemia, damaged 
mitochondria play a key role in contributing to oxidative stress and the activation of pro-
death signalling cascades in neurons post-ischaemia. At present, CARPs represent an exciting 
new class of pluripotent therapeutic for acute stroke due to their mitochondria-targeting and 
mitoprotective properties, as well as other neuroprotective actions. In particular, poly-
arginine peptides (such as R18 and R18D), which have been shown to have potent 
neuroprotective properties in experimental stroke models, warrant further preclinical 
evaluation prior to progressing to clinical trials. In addition, due to their multiple 
neuroprotective mechanisms of action, CARPs may have broader potential clinical 
application for the treatment of other forms of acute brain injury, as well as chronic 
neurodegenerative disorders.   
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Figure Legends 
 
Figure 1. Major biochemical pathways of the ischaemic cascade , which inevitably lead to 
irreversible cell death via apoptosis and necrosis. Insufficient oxygen for aerobic energy 
production results in diminished ATP levels, necessary for preservation of critical 
homeostatic functions, particularly maintenance of cellular ionic gradients. This disruption 
triggers mass release of excitatory neurotransmitters, which overstimulates calcium-
permeable ion channel receptors on post-synaptic neurons, causing massive calcium influx. 
This in turn triggers a number of key destructive events, collectively known as the ischaemic 
cascade, and include activation of calcium-sensitive proteases, free radical formation, and 
mitochondrial dysfunction. Mitochondria are central modulators in this cascade, and are both 
targets and contributors of the resulting injurious effects. 
 
AMPA, -amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid; ASIC, acid-sensing ion 
channel; Apaf-1, apoptotic protease activating factor 1; CICR, calcium-induced calcium 
release; cyt c, cytochrome c; CypD, cyclophilin D; ER, endoplasmic reticulum; I-V, 
mitochondrial ETC complexes; IP₃ R, inositol triphosphate receptor; MCU, mitochondrial 
calcium uniporter; MAM, mitochondria associated membranes; mNCX, mitochondrial 
sodium-calcium exchanger; mPTP, mitochondrial permeability transition pore; mRyR, 
mitochondrial ryanodine receptor; NCX, sodium-calcium exchanger; NMDA, N-methyl-D-
aspartate; PMCA, plasma membrane Ca²⁺ -ATPase; RaM, rapid mode calcium uptake; RyR, 
ryanodine receptor, TRPM, transient receptor potential ion channel; Smac, second 
mitochondria-derived activator of caspase; VDAC, voltage-dependent anion channel. 
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Figure 2. Mitochondrial ROS generation contributes to oxidative stress during ischaemic 
stroke. The IMM contains mitochondrial complexes I to V, which comprise the ETC. 
Electrons are transferred along the ETC in a stepwise fashion via electron carriers, including 
CoQ and cyt c, thereby releasing protons (H⁺ ) into the IMS. This accumulation of cations 
comprises the mitochondrial membrane potential (Δψm), which is required for ATP 
production by complex V. This process naturally generates low levels of ROS as a by-
product, which are metabolized by endogenous catabolic enzymes. However, during 
ischaemic stroke additional cellular stress turns mitochondria into the largest contributor of 
ROS in the brain. Consequently, electron ‘leak’ from complexes I and III are responsible for 
excess superoxide radical (O₂ •⁻ ) formation, which further reacts with endogenous 
manganese superoxide dismutase (MnSOD), or undergoes spontaneous dismutation to form 
toxic levels of hydrogen peroxide (H₂ O₂ ). H₂ O₂  subsequently reacts with transitional 
metals to further form hydroxyl radicals (•OH) via the Fenton reaction. Furthermore, NO• 
generated from nNOS as a result of calcium influx during ischaemic stroke are able to 
translocate to the mitochondria and react with O₂ •⁻  to form the highly toxic peroxynitrite 
(ONOO⁻ ). Collectively, the overproduction of these ROS plays a key role in cell death 
during stroke. 
 
CL, cardiolipin; CoQ, Coenzyme Q; e⁻ , electrons; H₂ O₂ , hydrogen peroxide; IMM, inner 
mitochondrial membrane; I-V, mitochondrial ETC complexes; IMS, intermembrane space; 
NO•, nitric oxide; O₂ •⁻ , superoxide; •OH, hydroxyl radical; OMM, outer mitochondrial 
membrane; ONOO⁻ , peroxynitrite; Δψm, mitochondrial membrane potential. 
 
 
 
 
Figure 3. Neuroprotective targets of CARPs during ischaemic stroke. A summation of 
documented and potential neuroprotective targets of CARPs that result from either direct 
and/or indirect mitochondrial protection, thereby preventing cell death. 
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Table 1. CARP sequences, cationic charge and arginine content of peptides named in review. 
 
Peptide Sequence1 
Net 
cha
rge 
(at 
pH
7) 
Argi
nine 
resid
ues 
Perce
ntage 
Argini
ne 
SS-
peptide
s 
    
SS-01, 
SS-02, 
SS-20, 
SS-31, 
mtCPP-
1 
YrFK-NH2, DmtrFK-NH2, FrFK-NH2, rDmtKF-NH2, rDmtOF-NH2 3 1 25% 
Poly-
arginin
e 
peptide
s 
    
R4 RRRR 4 4 100% 
R6 - R7 RRRRRR-NH2 - RRRRRRR-NH2 -1 
7-
Jun 
100% 
C-s-s-C-
R7 
C-s-s-CRRRRRRR-NH2 8 7 
77.80
% 
R9D rrrrrrrrr-NH2 10 9 100% 
R12 RRRRRRRRRRRR 12 12 100% 
R15 RRRRRRRRRRRRRRR 15 15 100% 
R18 
and 
R18D 
RRRRRRRRRRRRRRRRRR, rrrrrrrrrrrrrrrrrr 18 18 100% 
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Other 
CARPs 
        
Penetra
tin 
RQIKIWFQNRRMKWKK-NH2 8 3 
18.80
% 
Protami
ne 
PRRRRSSSRPVRRRRRPRVSRRRRRRGGRRRR 21 21 
65.60
% 
Hexape
ptides     
Hexape
ptides 
Ac-LCRRKF- NH2, Ac-RRWWIR- NH2, Ac-MCRRKR- NH2 -1 
3-
Feb 
33.3 - 
50% 
R4W2 RRRRWW- NH2 5 4 
66.70
% 
r4W2 rrrrWW- NH2 5 4 
66.70
% 
R5W RRRRRW- NH2 6 5 
83.30
% 
r5W rrrrrW- NH2 6 5 
83.30
% 
TAT 
and 
TAT-
fused 
peptide
s 
        
TAT48-57 
(TAT) 
GRKKRRQRRR 8 6 60% 
TAT-
NR2B9c 
(NA-1) 
YGRKKRRQRRR-KLSSIESDV 7 6 
31.60
% 
TAT-
NR2Bct 
GRKKRRQRRR-NRRRNSKLQHKKY 
14.
1 
9 
39.10
% 
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BVD-X 
protein 
and 
PX3 
peptide 
    
BVD-X2 
MSSDLRLTLLELVRRLNGNATIESGRLPGGRRRSPDTTTGTTGVTKTTEGPK
ECIDPTSRPAPEGPQEEPLHDLRPRPANRKGAAVE 
2 11 
12.60
% 
   SRPAPEGPQEEPLHDLRPRPANRKGAAVE-FRchaKFRChaK 
   
PX33 
  
4.2 6 
16.20
% 
 
 
 
1
Dmt = 2,6-dimethyltyrosine; O = ornithine; r = D-arginine;  Ac and NH2 = acetyl and amine side groups; cha = 
cyclohexyl-alanine. 
2
 BVD-X protein region used for PX3 peptide (bold). 
3
BVD-X-derived peptide fused to cell 
and mitochondrial penetrating peptide (underlined).  
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Table 2. Neuroprotective CARPs utilized in stroke and related CNS injury models. 
S
S
-p
e
p
ti
d
e
s 
Injury model  Route and 
schedule of 
administration 
Dose  Neuroprotection  Refs 
Hypoxia: 24h. 
 
H2O2 oxidative 
stress. 
 
G93A familial 
ALS model. 
 
Stroke (Rat): 
30min tMCAO. 
4h pre-
treatment. 
 
1h post H2O2. 
 
IP: daily. 
 
IP: multiple 
injections at 
immediately 
post (0h), 6, 
24, & 48h 
post-MCAO 
SS-31: 10 µM. 
 
SS-31: 1, 10, 100 µM. 
 
SS-31: 5 mg/kg/day. 
 
SS-31 and SS-20: 2 mg/kg.  
SS-31: 2 or 5 mg/kg.  
Reduced cell death, cytochrome c release, 
oxidative stress, and caspase-3 activation; 
prevented p66Shc activation. 
Reduced cell death. 
 
Improved survival and motor performance; 
reduced cell loss in spinal cord, and levels of 
lipid peroxidation and protein nitration. 
SS-31 only prevented ischaemia-induced 
cortical GSH depletion; reduced infarct 
volume 
[250] 
 
[251] 
 
[251] 
 
[253] 
P
o
ly
-a
rg
in
in
e
 p
e
p
ti
d
e
s 
 
Glutamate 
excitotoxicity. 
 
 
 
Oxygen-glucose 
deprivation. 
 
 
 
Stroke (Rat): 
30min pMCAO. 
 
                       
                        
 
 
                       
90min tMCAO. 
                     
120min tMCAO. 
                     
180min tMCAO.  
 
NMDA 
excitotoxicity. 
 
 
 
Kainic acid 
excitotoxicity. 
 
10-15min 
peptide pre-
treatment 
and/or during 
glutamate 
exposure. 
10min peptide 
pre-treatment 
at 1-6h prior 
or 0-45min 
post-
glutamate 
exposure. 
Concurrent 
peptide 
incubation with 
OGD. 
24h exposure 
post-OGD. 
15min exposure 
post-OGD. 
10min exposure 
pre-OGD 1-3h 
prior. 
IV: 30min post-
MCAO onset. 
 
 
 
IV: 60min post-
MCAO onset. 
IV: 120min 
post-MCAO 
onset . 
IV: 150min 
post-MCAO 
onset . 
ICA: 120min 
post-MCAO 
onset . 
IV: 300min 
post-MCAO 
onset . 
 
5min prior and 
during NMDA 
exposure. 
Intravitreal 
injections (3 
µL) of C-s-s-
C-R7 peptide 
2h prior to 
 
R6 to R15, R18 and 
tryptophan-containing poly-
arginine peptides 0.5-15 µM. 
 
 
R6 to R15, R18 and 
tryptophan-containing poly-
arginine peptides 0.5-15 µM. 
 
 
R18 or R12W8: 1000 
nmol/kg; R9D; 30 nmol/kg. 
 
R12, R15, or R18: 1000 
nmol/kg; R18 and R18D: 
1000 nmol/kg. 
R18: 100, 300, 1000 
nmol/kg. 
R18: 1000 nmol/kg. 
R18: 30, 100, 300, 1000 
nmol/kg. 
R18: 100 nmol/kg R18. 
R18: 1000 nmol/kg R18. 
 
R12: 1 or 2 µM R12. 
Cyclic poly-arginine 
peptides: 1.5, 3, 6 nM. 
 
 
R9: 1, 5, 10, 15 µM. 
 
Protected against excitotoxicity and reduced 
calcium influx. 
 
Protected against excitotoxicity up to 6h prior 
to and 45min post-glutamate. 
Protected against OGD. 
Protected against OGD. 
Protected against OGD. 
Protected against OGD up to 2h prior. 
Reduced infarct volume and cerebral oedema; 
reduced hemisphere swelling. 
R12 and R18, and to a greater extent, R18D, 
reduced total infarct volume. 
Reduced infarct volume and improved 
functional outcomes. 
Reduced cerebral oedema and improved 
neurological score. 
Reduced infarct volume and hemisphere 
swelling. 
Mild reduction in infarct volume. 
Mild reduction in cerebral oedema and 
improvement in neurological score with R18. 
Protected against excitotoxicity. 
Inhibited NMDA-induced PARP-1 activation; 
reduced mitochondrial oxidative stress and 
attenuated mitochondrial membrane 
hyperpolarization. 
Protected against excitotoxicity. 
 
 
[156, 
160, 
161, 
256] 
[219] 
 
[219] 
[256] 
[219] 
[219] 
[161, 
219] 
 
[265, 
269] 
 
[266] 
[267] 
[162] 
[267] 
[267] 
 
[219] 
[264] 
 
 
[256] 
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successive 
injection with 
NMDA (20 
nM). 
15min pre-
treatment. 
P
e
n
e
tr
a
ti
n
, 
P
ro
ta
m
in
e
 a
n
d
  
H
e
x
a
p
e
p
ti
d
e
s 
 
Glutamate 
excitotoxicity. 
 
 
Kainic acid 
excitotoxicity. 
Oxygen-glucose 
deprivation. 
Stroke (Rat): 
30min pMCAO. 
 
NMDA 
excitotoxicity. 
 
15min prior to 
glutamic acid 
exposure. 
10min peptide 
incubation 0, 
1, and 2h 
prior to 
glutamic acid 
exposure. 
15min prior to 
kainic acid 
exposure. 
Concurrent 
peptide 
incubation 
with OGD. 
IV: 30min post-
MCAO onset.  
 
Concurrent 
treatment 
with NMDA 
exposure for 
20min. 
 
Penetratin: 1, 5, 10, 15 µM.  
Protamine and Pmt1-4: 1, 2, 
5 µM  
 
Penetratin: 1, 5, 10, 15 µM. 
Penetratin: 1, 2, 5, 10 µM. 
Protamine 1000 nmol/kg. 
 
Hexapeptides: 10 µM. 
 
Protected against excitotoxicity. 
Protected against excitotoxicity up to 2h prior 
to glutamate. 
 
Protected against excitotoxicity. 
Protected against OGD. 
Reduced infarct volume and cerebral oedema; 
improved neurological score. 
Protected against excitotoxicity. 
 
[256] 
[161] 
 
[256] 
[256] 
[161] 
 
[262] 
T
A
T
 a
n
d
 T
A
T
-f
u
se
d
 
p
e
p
ti
d
e
s 
 
Glutamate 
excitotoxicity. 
 
 
Kainic acid 
excitotoxicity. 
Oxygen-glucose 
deprivation. 
NMDA 
excitotoxicity. 
 
Stroke (Rat): 
30min pMCAO. 
                      
90min tMCAO. 
                    
120min tMCAO. 
                    
180min tMCAO. 
 
 
10-15min prior 
to or at 
intervals (0, 
15, 30, 45, or 
60min) post 
glutamic acid 
exposure. 
15min prior to 
kainic acid 
exposure. 
Concurrent 
peptide 
incubation. 
Simultaneous 
TAT 
treatment or 
15min prior 
to and during 
NMDA 
exposure. 
IV: 60min post-
MCAO onset. 
IV: 150min 
post-MCAO 
onset. 
 
TAT or TAT-conjugated 
peptides, both L- and D-
isoforms: 0.1-15 µM; TAT-
NR2B9c: 1, 2, 5, 10 µM. 
 
D-TAT and TAT-conjugates: 
1-15 µM. 
D-TAT: 1, 2, 5, 10 µM. 
TAT and D-TAT pre-
treatment: 5, 10 µM; 
TAT-NR2B9c: 2, 5, 10 µM. 
TAT-NR2B9c: 100, 300, 
1000 nmol/kg. 
TAT-NR2B9c: 30, 100, 300, 
1000 nmol/kg. 
TAT-NR2B9c: 100 nmol/kg. 
TAT-NR2B9c: 1000 
nmol/kg. 
 
 
Protected against excitotoxicity. 
  
 
Reduced calcium influx. 
Protected against OGD. 
Protected against excitotoxicity. 
 
Reduced infarct volume and improved 
functional outcomes. 
Mild reduction in infarct volume and 
hemisphere swelling. 
No neuroprotection. 
No neuroprotection; therapeutic window <2h. 
 
 
[219, 
256, 
258, 
259] 
 
[256] 
[219, 
256] 
[219] 
 
[266] 
[162] 
[267] 
[267] 
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ICA: 120min 
post-MCAO 
onset. 
IV: 300min 
post-MCAO 
onset. 
 
B
V
D
-X
 p
ro
te
in
 a
n
d
 P
X
3
 p
e
p
ti
d
e
 
 
Fas-mediated 
apoptosis. 
 
Glucose oxidase 
(GOX)-
induced death-
receptor-
independent 
apoptosis. 
MPTP PD 
neurodegenerat
ion model 
(Mouse) 
 
 
 
 
 
 
 
MPP+ toxicity. 
 
Rotenone-induced 
oxidative 
stress. 
 
10µg/mL α-Fas 
antibody to 
stimulate Fas-
induced 
apoptosis. 
1.5 or 2h 
incubation 
with 
2mU/mL 
GOX. 
 
 
Stereotaxic 
injection 
with WT 
(LV-XWT) or 
mutant X 
protein 
(XA6A7) 2wk 
prior to 
MPTP 
intoxication 
model. 
ICV: PX3 
daily, 1 day 
before IP 
MPTP 
intoxication 
and during 
first 4 days 
post-MPTP. 
Intranasal 
administratio
n: PX3 daily, 
1 day before 
IP MPTP 
intoxication 
and during 
first 4 days 
post-MPTP. 
WT (BVDWT) 
or mutant 
(BDV-XA6A7) 
X protein. 
WT or mutant 
X protein 
(XA6A7), or 
un-
transfected 
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Increased mitochondrial filamentation and 
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ICA = intracerebral artery; ICV = intracerebral vessel; IP = intraperitoneal; IV = intravenous; MCAO = middle cerebral artery occlusion; OGD = 
oxygen-glucose deprivation; PD; Parkinson’s disease. 
  
proteins (X, 
XΔ2-4 and 
XA4). 
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Highlights 
 There are currently no clinically effective neuroprotective therapeutics available for 
stroke patients. 
 Mitochondria have been highlighted as a critical central mediator in determining the 
cellular fate of neuronal and glial cells during stroke. 
 Cationic arginine-rich peptides (CARPs) are an emerging class of novel 
neuroprotective agents that have demonstrated potent neuroprotection by targeting 
mitochondria during stroke. 
 Mito-protection may represent a new avenue of targeted drug development, and 
translate to better clinical outcomes in stroke trials. 
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